No replenishment of carnitine from trimethyllysine during pivalate- induced carnitine loss in humans

Béla Melegh, Maria Pap, Gabriella Szekely, Douglas A. Gage, A. Dean Sherry, Loran L. Bieber

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pivaloylcarnitine formation from exogenous carnitine and from carnitine precursor 6-N-trimethyllysine was investigated in two groups of pivampicillin treated subjects. In the first group, medication of pivampicillin led to the formation of and urinary excretion of pivaloylcarnitine. Oral L-carnitine supplementation, introduced after the third day of treatment, caused 2 fold urinary excretion of carnitine esters. For this group, the plasma levels and urinary output of butyrobetaine also decreased on the third day of pivampicillin treatment, but it normalized after carnitine administration. In contrast, urinary output of the carnitine precursor, trimethyllysine did not change during the study period. For the second group, oral trimethyllysine supplementation was started on the 4th day of pivampicillin treatment. Administration of trimethyllysine had no effect on the urinary output of carnitine esters, although the urinary excretion of it increased from approximately 25 to 450 μmol/day. Plasma levels and urinary output of butyrobetaine decreased during the pivampicillin treatment and administration of trimethyllysine did not restore the levels. Administration of trimethyllysine produced a large increase in urinary trimethyllysine output, but it did not affect the fast atom bombardment mass spectrometry signal intensity of other carnitine precursors. The urinary metabolite profile shows, that the conversion process of trimethyllysine to hydroxy- trimethyllysine represent an obstacle in butyrobetaine and carnitine biosynthesis in humans in vivo. Because the administered trimethyllysine was not converted to carnitine or carnitine precursors to any significant extent, its nutritional value with respect to the replenishment of carnitine reserves is questionable.

Original languageEnglish (US)
Pages (from-to)147-151
Number of pages5
JournalJournal of Nutritional Biochemistry
Volume8
Issue number3
DOIs
StatePublished - Mar 1997

Fingerprint

Carnitine
Pivampicillin
trimethyllysine
Esters
Fast Atom Bombardment Mass Spectrometry
Plasmas
Biosynthesis
Nutritive Value
Metabolites
Mass spectrometry

Keywords

  • carnitine
  • pivaloyl-carnitine
  • pivampicillin
  • trimethyllysine

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

No replenishment of carnitine from trimethyllysine during pivalate- induced carnitine loss in humans. / Melegh, Béla; Pap, Maria; Szekely, Gabriella; Gage, Douglas A.; Sherry, A. Dean; Bieber, Loran L.

In: Journal of Nutritional Biochemistry, Vol. 8, No. 3, 03.1997, p. 147-151.

Research output: Contribution to journalArticle

Melegh, Béla ; Pap, Maria ; Szekely, Gabriella ; Gage, Douglas A. ; Sherry, A. Dean ; Bieber, Loran L. / No replenishment of carnitine from trimethyllysine during pivalate- induced carnitine loss in humans. In: Journal of Nutritional Biochemistry. 1997 ; Vol. 8, No. 3. pp. 147-151.
@article{eb85360fff7d4dd6a1dfae2b8e2da61e,
title = "No replenishment of carnitine from trimethyllysine during pivalate- induced carnitine loss in humans",
abstract = "Pivaloylcarnitine formation from exogenous carnitine and from carnitine precursor 6-N-trimethyllysine was investigated in two groups of pivampicillin treated subjects. In the first group, medication of pivampicillin led to the formation of and urinary excretion of pivaloylcarnitine. Oral L-carnitine supplementation, introduced after the third day of treatment, caused 2 fold urinary excretion of carnitine esters. For this group, the plasma levels and urinary output of butyrobetaine also decreased on the third day of pivampicillin treatment, but it normalized after carnitine administration. In contrast, urinary output of the carnitine precursor, trimethyllysine did not change during the study period. For the second group, oral trimethyllysine supplementation was started on the 4th day of pivampicillin treatment. Administration of trimethyllysine had no effect on the urinary output of carnitine esters, although the urinary excretion of it increased from approximately 25 to 450 μmol/day. Plasma levels and urinary output of butyrobetaine decreased during the pivampicillin treatment and administration of trimethyllysine did not restore the levels. Administration of trimethyllysine produced a large increase in urinary trimethyllysine output, but it did not affect the fast atom bombardment mass spectrometry signal intensity of other carnitine precursors. The urinary metabolite profile shows, that the conversion process of trimethyllysine to hydroxy- trimethyllysine represent an obstacle in butyrobetaine and carnitine biosynthesis in humans in vivo. Because the administered trimethyllysine was not converted to carnitine or carnitine precursors to any significant extent, its nutritional value with respect to the replenishment of carnitine reserves is questionable.",
keywords = "carnitine, pivaloyl-carnitine, pivampicillin, trimethyllysine",
author = "B{\'e}la Melegh and Maria Pap and Gabriella Szekely and Gage, {Douglas A.} and Sherry, {A. Dean} and Bieber, {Loran L.}",
year = "1997",
month = "3",
doi = "10.1016/S0955-2863(97)00013-2",
language = "English (US)",
volume = "8",
pages = "147--151",
journal = "Journal of Nutritional Biochemistry",
issn = "0955-2863",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - No replenishment of carnitine from trimethyllysine during pivalate- induced carnitine loss in humans

AU - Melegh, Béla

AU - Pap, Maria

AU - Szekely, Gabriella

AU - Gage, Douglas A.

AU - Sherry, A. Dean

AU - Bieber, Loran L.

PY - 1997/3

Y1 - 1997/3

N2 - Pivaloylcarnitine formation from exogenous carnitine and from carnitine precursor 6-N-trimethyllysine was investigated in two groups of pivampicillin treated subjects. In the first group, medication of pivampicillin led to the formation of and urinary excretion of pivaloylcarnitine. Oral L-carnitine supplementation, introduced after the third day of treatment, caused 2 fold urinary excretion of carnitine esters. For this group, the plasma levels and urinary output of butyrobetaine also decreased on the third day of pivampicillin treatment, but it normalized after carnitine administration. In contrast, urinary output of the carnitine precursor, trimethyllysine did not change during the study period. For the second group, oral trimethyllysine supplementation was started on the 4th day of pivampicillin treatment. Administration of trimethyllysine had no effect on the urinary output of carnitine esters, although the urinary excretion of it increased from approximately 25 to 450 μmol/day. Plasma levels and urinary output of butyrobetaine decreased during the pivampicillin treatment and administration of trimethyllysine did not restore the levels. Administration of trimethyllysine produced a large increase in urinary trimethyllysine output, but it did not affect the fast atom bombardment mass spectrometry signal intensity of other carnitine precursors. The urinary metabolite profile shows, that the conversion process of trimethyllysine to hydroxy- trimethyllysine represent an obstacle in butyrobetaine and carnitine biosynthesis in humans in vivo. Because the administered trimethyllysine was not converted to carnitine or carnitine precursors to any significant extent, its nutritional value with respect to the replenishment of carnitine reserves is questionable.

AB - Pivaloylcarnitine formation from exogenous carnitine and from carnitine precursor 6-N-trimethyllysine was investigated in two groups of pivampicillin treated subjects. In the first group, medication of pivampicillin led to the formation of and urinary excretion of pivaloylcarnitine. Oral L-carnitine supplementation, introduced after the third day of treatment, caused 2 fold urinary excretion of carnitine esters. For this group, the plasma levels and urinary output of butyrobetaine also decreased on the third day of pivampicillin treatment, but it normalized after carnitine administration. In contrast, urinary output of the carnitine precursor, trimethyllysine did not change during the study period. For the second group, oral trimethyllysine supplementation was started on the 4th day of pivampicillin treatment. Administration of trimethyllysine had no effect on the urinary output of carnitine esters, although the urinary excretion of it increased from approximately 25 to 450 μmol/day. Plasma levels and urinary output of butyrobetaine decreased during the pivampicillin treatment and administration of trimethyllysine did not restore the levels. Administration of trimethyllysine produced a large increase in urinary trimethyllysine output, but it did not affect the fast atom bombardment mass spectrometry signal intensity of other carnitine precursors. The urinary metabolite profile shows, that the conversion process of trimethyllysine to hydroxy- trimethyllysine represent an obstacle in butyrobetaine and carnitine biosynthesis in humans in vivo. Because the administered trimethyllysine was not converted to carnitine or carnitine precursors to any significant extent, its nutritional value with respect to the replenishment of carnitine reserves is questionable.

KW - carnitine

KW - pivaloyl-carnitine

KW - pivampicillin

KW - trimethyllysine

UR - http://www.scopus.com/inward/record.url?scp=0030909810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030909810&partnerID=8YFLogxK

U2 - 10.1016/S0955-2863(97)00013-2

DO - 10.1016/S0955-2863(97)00013-2

M3 - Article

AN - SCOPUS:0030909810

VL - 8

SP - 147

EP - 151

JO - Journal of Nutritional Biochemistry

JF - Journal of Nutritional Biochemistry

SN - 0955-2863

IS - 3

ER -